Compare Adaptive Biotechnologies Corp (ADPT) vs AMETEK, Inc. (AME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs AMETEK, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while AMETEK, Inc. trades at $228.58 (market cap $53.11B). The key difference: AMETEK, Inc. is far larger — about 15.9× Adaptive Biotechnologies Corp's market cap, and AMETEK, Inc. pays a 0.59% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AME | |
|---|---|---|
Market Cap | $3.33B | $53.11B |
Sector | Health | Industrials |
52-Week High | $22.37 | $241.94 |
52-Week Low | $10.24 | $176.44 |
Enterprise Value | $3.19B | $54.80B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AME trades at $231.70, down 1.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $263.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.97 exceeding expectations. Revenue grew to $7.40 billion in 2025, and net income margin improved to 20.11%. Recent acquisitions, including First Aviation Services and the Indicor Instrumentation group for $5 billion, aim to expand its aerospace and industrial technology footprint.
The outlook for AME is positive, supported by earnings momentum, strategic acquisitions, and solid profitability. Risks include integration challenges from large acquisitions and elevated valuation multiples, such as a P/E of 35.82. With no sell ratings from analysts and institutional backing, the stock presents a growth opportunity, though investors should monitor execution on acquisition synergies and macroeconomic conditions affecting industrial demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →
